1.18

11.32% 0.12

After Hours: 1.18

Gossamer Bio Inc (GOSS)

Overview News Price History Option Chain Financials Discussions Forecast

Gossamer Bio Inc stock is traded at $1.18, with a volume of 2.62M. It is up +11.32% in the last 24 hours and up +20.59% over the past month. Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Previous Close:

$1.06

Open:

$1.06

24h Volume:

2.62M

Relative Volume:

1.59

Market Cap:

$217.75M

Revenue:

Net Income/Loss:

$-179.82M

P/E Ratio:

-0.8872

EPS:

-1.33

Net Cash Flow:

$-159.16M

1W Performance:

+23.13%

1M Performance:

+20.59%

6M Performance:

+35.06%

1Y Performance:

+52.99%

1-Day Range:

$1.0401

$1.23

1-Week Range:

$0.8451

$1.23

52-Week Range:

$0.4993

$1.55

Gossamer Bio Inc Stock (GOSS) Company Profile

Name

Gossamer Bio Inc

Sector

Healthcare (1152)

Industry

Biotechnology (677)

Phone

(858) 684-1300

Address

3115 MERRYFIELD ROW, SAN DIEGO, CA

Employee

145

Twitter

@GossamerBio

Next Earnings Date

2024-11-07

Latest SEC Filings

GOSS's Discussions on Twitter

Compare GOSS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GOSS Gossamer Bio Inc	1.18	217.75M	0	-179.82M	-159.16M	-1.33
VRTX Vertex Pharmaceuticals Inc	501.15	126.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	605.61	65.06B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	649.67	37.54B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	259.39	32.56B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	255.77	26.40B	3.81B	-644.79M	-669.77M	-6.24

Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-25-24	Initiated	Oppenheimer	Outperform
Apr-05-24	Resumed	Wedbush	Outperform
Jul-27-23	Downgrade	UBS	Buy → Neutral
Mar-07-23	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-23	Initiated	Guggenheim	Neutral
Dec-07-22	Downgrade	Barclays	Overweight → Equal Weight
Dec-07-22	Downgrade	JP Morgan	Neutral → Underweight
Dec-07-22	Downgrade	SMBC Nikko	Outperform → Neutral
Oct-20-22	Initiated	Goldman	Buy
Sep-21-22	Initiated	JP Morgan	Neutral
Sep-19-22	Initiated	Wedbush	Outperform
Apr-18-22	Initiated	Raymond James	Outperform
Apr-06-22	Initiated	UBS	Buy
Jan-10-22	Upgrade	SMBC Nikko	Neutral → Outperform
Nov-09-21	Resumed	Cantor Fitzgerald	Overweight
Sep-21-21	Resumed	Piper Sandler	Overweight
Jun-29-20	Initiated	H.C. Wainwright	Buy
Apr-22-20	Initiated	Piper Sandler	Overweight
Feb-27-20	Initiated	Barclays	Overweight
Dec-03-19	Resumed	BofA/Merrill	Buy
Oct-30-19	Initiated	Berenberg	Buy
Mar-05-19	Initiated	Barclays	Overweight
Mar-05-19	Initiated	BofA/Merrill	Buy
Mar-05-19	Initiated	Evercore ISI	Outperform
Mar-05-19	Initiated	SVB Leerink	Outperform

View All

Gossamer Bio Inc Stock (GOSS) Latest News

01:21 AM

Gossamer Bio: Initiating Hold As Late‐Stage Data Nears Inflection (GOSS) - Seeking Alpha

01:21 AM

May 01, 2025

Selling Buzz: Gossamer Bio Inc [GOSS] Chief Medical Officer Aranda Richard sells 1,908 shares of the company - knoxdaily.com

May 01, 2025

Apr 30, 2025

Check out these key findings about Gossamer Bio Inc (GOSS) - Sete News

Apr 30, 2025

Geode Capital Management LLC Has $2.04 Million Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World

Apr 30, 2025

Apr 29, 2025

Was Gossamer Bio Inc (GOSS)’s session last reading good? - uspostnews.com

Apr 29, 2025